Evommune's pre-market share price fell 18.1%. Previously, the eczema drug developed by the company did not reach the main end of the mid-term trial.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.